ClinicalTrials.gg
Sign In
Not yet recruitingNCT07832916Updated Sep 22, 2026

Comparison Between Turbinoplasty Techniques in Chronic Nasal Obstruction Microdebrider Coblation andSubmucosalBipolarDiathermyTechniquesduetohypertrophoidturbinate

An interventional study of Submucosal Bipolar Diathermy Assisted Turbinoplasty and Coblation-Assisted Turbinoplasty in Chronic Nasal Obstruction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Chronic nasal obstruction is one of the most common complaints in otorhinolaryngology practice, with inferior turbinate hypertrophy being a major anatomical cause that significantly impairs nasal airflow and quality of life.(1) It is commonly associated with allergic rhinitis, vasomotor rhinitis, chronic rhinosinusitis, and compensatory hypertrophy secondary to septal deviation. (2) When medical treatment fails, surgical reduction of the inferior turbinate becomes necessary.(2) Available techniques include Microdebrider (3) , Coblation(4), and Submucosal Bipolar Diathermy(5) aim to reduce turbinate volume while maintaining normal mucosal function and are associated with less tissue damage than conventional procedures. (6) Although several surgical techniques have shown good clinical outcomes, no single method has been established as the gold standard. Comparative evidence evaluating microdebrider, coblation, and bipolar in the same prospective study remains limited,(7) particularly in the Egyptian population.

Therefore, this study aims to compare these techniques regarding efficacy, safety, postoperative outcomes, and patient satisfaction to provide evidence that supports appropriate surgical decision-making

02

Conditions studied

  • Chronic Nasal Obstruction

Browse trials for

03

In context

Nasal Obstruction

173 studies on the registry are indexed under Nasal Obstruction; 31 are open to participants now.

This study's planned enrollment of 66 is close to the median of 70 across 139 interventional studies indexed under Nasal Obstruction.

Browse Nasal Obstruction studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Assiut University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18- 60 years of either sex.
  • Chronic nasal obstruction of more than 3 months' duration attributable to bilateral inferior turbinate hypertrophy (Grade II or III on endoscopic grading).

Exclusion criteria

Exclusion Criteria:

  • Nasal obstruction primarily attributable to severe septal deviation requiring septoplasty as the main corrective procedure.
  • Chronic rhinosinusitis with nasal polyposis.
  • Nasal or paranasal sinus tumors/masses.
  • Previous nasal, turbinate, or sinus surgery.
  • Atrophic rhinitis or empty nose syndrome.
  • Uncontrolled bleeding disorders or use of anticoagulant/antiplatelet therapy that cannot be safely withheld.
  • Uncontrolled systemic disease (e.g., uncontrolled diabetes mellitus, hypertension) precluding surgery/anesthesia.
  • Pregnancy.
  • Active nasal infection at the time of surgery.
  • Patient refusal to participate or to complete follow-up.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    Group A

    Microdebrider-Assisted Turbinoplasty

    Procedure: Microdebrider-Assisted Turbinoplasty

  • Active comparator
    Group B

    Coblation-Assisted Turbinoplasty

    Procedure: Coblation-Assisted Turbinoplasty

  • Active comparator
    Group c

    Submucosal Bipolar Diathermy Assisted Turbinoplasty

    Procedure: Submucosal Bipolar Diathermy Assisted Turbinoplasty

Interventions

  • ProcedureSubmucosal Bipolar Diathermy Assisted Turbinoplasty

    minimally invasive surgical procedure used to shrink enlarged inferior nasal turbinates and improve nasal breathing

  • ProcedureCoblation-Assisted Turbinoplasty

    a minimally invasive surgical procedure that uses low-temperature radiofrequency plasma energy to shrink enlarged nasal turbinates and improve breathing

  • ProcedureMicrodebrider-Assisted Turbinoplasty

    a minimally invasive surgical procedure used to reduce the size of enlarged inferior turbinates

06

What researchers measure

Primary outcomes

  1. Change in endoscopic inferior turbinate grade

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 39 non-industry interventional studies with no phase under Nasal Obstruction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 60 studies reached it within 18 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 22, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07832916
Lead sponsor
Assiut University
Responsible party
Mary Zakaria Fam Sedhom (residant doctor at Assiut university hospital, Assiut University) — Principal investigator
First posted
Sep 22, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nasal Obstruction →

Other studies from this sponsor

Assiut University →

Start the discussion